Tech Center 1600 • Art Units: 1628 1629
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19304725 | PYRAZOLESULFONAMIDES AS ANTITUMOR AGENTS | Non-Final OA | Peloton Therapeutics, Inc., a fully owned subsidiary of Merck Sharp & Dohme LLC |
| 18514478 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | Non-Final OA | Hoffmann-La Roche Inc. |
| 18255076 | NEW INDAZOLE DERIVATIVES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18023211 | KAEMPFEROL AGLYCONE-CONTAINING EXTRACT | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17761020 | METHODS OF TREATING PHOSPHATE CONCENTRATION DISORDERS WITH L-BAIBA | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17622121 | COMPOUNDS HAVING ANTIMALARIAL ACTIVITY | Final Rejection | NANYANG TECHNOLOGICAL UNIVERSITY |
| 16812140 | CRISPR and LASER ART Eliminates HIV | Non-Final OA | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
| 18037949 | Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid | Non-Final OA | Sanofi |
| 18265335 | COMPOSITIONS AND METHODS FOR INHIBITING M PRO PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-COV-2 INFECTION | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 17612074 | Substituted 4-[5-(Benzofuran-2-yl)-1,2,4-Oxadiazol-3-yl]Benzoic Acid Compounds for Use in Therapy for Neuropathic Pain | Non-Final OA | King's College London |
| 18547950 | Solid Personal Care Compositions and Methods for Preventing and Treating Pollution Damage to Skin | Final Rejection | Colgate-Palmolive Company |
| 18035152 | Use of 5-HT3-Targeting Drugs for Treatment of Acute Kidney Injury | Non-Final OA | University of Pittsburgh-Of the Commonwealth System of Higher Education |
| 17596495 | SMARCA INHIBITORS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 18362634 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18032612 | CONJUGATED TLR7 AND NOD2 AGONISTS | Non-Final OA | UNIVERZA V LJUBLJANI |
| 18282096 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P.A. |
| 18282079 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Non-Final OA | CHIESI FARMACEUTICI S.P. A. |
| 18608109 | PHARMACEUTICAL PREPARATION | Final Rejection | KOWA COMPANY, LTD. |
| 18276334 | PYRIMIDINE AROMATIC RING COMPOUNDS | Non-Final OA | Usynova Pharmaceuticals Ltd. |
| 18547794 | RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Non-Final OA | Boundless Bio, Inc. |
| 18256089 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Erasca, Inc. |
| 18547763 | NITROTHIAZOLE DERIVATIVE AND APPLICATION THEREOF | Non-Final OA | CHENGDU BIOBEL BIOTECHNOLOGY CO., LTD. |
| 17922336 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | Non-Final OA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 18559466 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST GLUCOSYLCERAMIDE SYNTHASE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Non-Final OA | GREEN CROSS CORPORATION |
| 17623925 | METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE | Final Rejection | ORION CORPORATION |
| 18282177 | CRYSTALLINE FORM OF HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | Non-Final OA | HK INNO.N CORPORATION |
| 17623331 | APPLICATION OF PROGESTIN IN PREPARATION OF DRUG INHIBITING CYTOKINE STORM | Final Rejection | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. |
| 18250876 | COMPOSITION COMPRISING CATIONIC SUBSTANCE, AND USE FOR SAME | Final Rejection | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18279708 | CXCL8 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF FOR USE IN THE TREATMENT OF SEIZURES | Non-Final OA | DOMPE' FARMACEUTICI SPA |
| 18548014 | COMPOUND FOR TREATMENT OF COGNITIVE DISORDERS | Non-Final OA | Syndesi Therapeutics SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy